NCT02395250View on ClinicalTrials.gov

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

November 30, 2018

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

anti-GPC3 CAR T

Trial Locations (1)

200032

Shanghai Cancer Institute, Xuhui

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT02395250 - Anti-GPC3 CAR T for Treating Patients With Advanced HCC | Biotech Hunter | Biotech Hunter